Cannabis Law Report

JUNE 23, 2021

NEO: AWKN) began trading today, June 23, 2021, on the NEO Exchange Inc. The company has plans to open three UK psychedelic-assisted psychotherapy clinics where it will deliver ketamine-assisted therapies near term and MDMA when they secure authorization in 2021 (Bristol, London, and Manchester). David Nutt), starts in Q4 2021.

Clinical Trials 110

Clinical Trials Therapy Research and Development Treatment 110

Cannabis Law Report

DECEMBER 9, 2021

Published: Dec 08, 2021. 08, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. The Company believes it has produced a sufficient supply of cGMP DMT to complete its planned Phase 1 and Phase 2 clinical trials. as medical consultants to the Company’s DMT stroke clinical research program.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JUNE 17, 2021

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) raised its full-year 2021 financial guidance based on the acquisition of GW Pharmaceuticals, which was bought on May 5, 2021. The May 4, 2021 guidance for revenue was in the range of $2.5 – $2.7 That has been increased as of June 17, 2021, to a range of $3.0

Pharmaceutical 108

Pharmaceutical Clinical Trials Therapy Programs 108

Cannabis Law Report

AUGUST 17, 2021

Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. A global Phase 3 randomized, double blind, placebo-controlled trial (TrustTSC) of adjunctive ganaxolone in approximately 160 TSC patients is expected to begin enrollment during Q4 2021. RADNOR, Pa.–(BUSINESS

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

DECEMBER 26, 2021

December 17, 2021 ·. – December 16, 2021) – Entheon Biomedical Corp. In furtherance of its program, the Company filed US Provisional Patent Application No. 63/283,051, titled “Detection of Therapeutic Psychedelic State,” as of November 23, 2021. Vancouver, British Columbia–(Newsfile Corp.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

The Cannigma

OCTOBER 14, 2022

San Marino medical marijuana program. The program does not include cannabis flower or home grow. The program does not include cannabis flower or home grow. This medication is provided at no cost to residents of the country. Is CBD legal in San Marino? CBD has not been specifically legalized in San Marino.

Law 56

Law Clinical Trials Research and Development Recreational 56

Cannabis Law Report

JUNE 11, 2021

NEW YORK, June 9, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines, announces that J.R. Here’s the press release. This all could not have been possible without you.”.

Clinical Trials 95

Clinical Trials Research and Development Pharmaceutical Medicine 95

Cannabis Law Report

JANUARY 12, 2022

“We can now concentrate all our energies on advancing our plant-inspired, biopharmaceutical research and development programs into human clinical trials.” 14, 2021, the sale of Gb Sciences’ Las Vegas cannabis facility was finalized on Dec. and three issued international patents, as well as 12 U.S.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

AUGUST 2, 2021

2, 2021 /PRNewswire/ — Bionomics Limited (ASX: BNO,OTCQB: BNOEF ), ( Bionomics ) a global, clinical stage biopharmaceutical company, is pleased to announce that it plans to conduct a registered initial public offering of American Depositary Shares ( ADSs ) in the United States and a concurrent listing of ADSs on Nasdaq.

Clinical Trials 105

Clinical Trials Research and Development Treatment Conditions 105

MedicalJane

OCTOBER 3, 2019

The United States Department of Defense and GW Pharmaceuticals are collaborating on a new clinical trial at the Montefiore Medical Center in New York. Dr. Eric Hollander, the Director of the Autism and Obsessive Compulsive Spectrum Program and Anxiety and Depression Program at Montefiore Hospital, is leading the clinical trial.

Clinical Trials 74

Clinical Trials Epilepsy Pharmaceutical Treatment 74

Cannabis Law Report

AUGUST 3, 2021

Cybin was well funded before this financing, and this new funding now further extends the runway for our drug programs, discovery pipeline and IP portfolio, and provides additional flexibility to support potential M&A opportunities. Vigorous scientific research and clinical trials are needed.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

SpeedWeed

AUGUST 11, 2021

The grant comes from Michigan’s 2021 Veteran Marijuana Research Grant Program , and is funded by the state’s recreational cannabis taxes. We overcame significant regulatory obstacles obstructing cannabis research to conduct the first clinical trial of inhaled cannabis for PTSD ,” said Yazar-Klosinki. .

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical DEA 52

SpeedWeed

SEPTEMBER 17, 2021

Data collected from MAPS-sponsored Phase 3 clinical trials suggests that MDMA-assisted therapy appears promising in the treatment of TBI. Wesana outlined five key goals: Gain expertise and information to design psychedelic-assisted therapy programs for TBI and improve the Wesana timeline and path to market for its treatments.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

Cannabis Law Report

MAY 10, 2022

Medicinal cannabis products such as capsules, creams, oils, lozenges, sprays and granulated flowers were approved for prescription 159,665 times between the start of Australia’s medicinal cannabis program in February 2016 and September 2021, research led by the University of Sydney’s Lambert Initiative for Cannabinoid Therapeutics shows.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Cannabis Law Report

JUNE 7, 2021

NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its program development partner, Evvivax, S.R.L. Hurry, 917-733-5573, sanjay.hurry@adnas.com Program contact: Brian Viscount, 631-240-8877, brian.viscount@adnas.com Web: www.adnas.com Twitter: @APDN.

Clinical Trials 64

Clinical Trials Research and Development Therapy Supply Chain 64

Cannabis Law Report

SEPTEMBER 2, 2021

– Company’s safeCircle™ Testing Program to Monitor for COVID-19 Among On-Campus Unvaccinated Populations –. Testing is scheduled to begin in the second half of September 2021. Under the Contract, ADCL will deploy safeCircle™, its high-throughput, pooled COVID-19 testing program, to provide cost-effective COVID-19 testing.

Clinical Trials 99

Clinical Trials Research and Development Therapy Collective 99

Cannabis Law Report

JUNE 30, 2021

s (CSE: MXT) (OTC: MXTTF) SHAMAN and YMI programs apply machine learning to high-resolution health records to better diagnose mental health disorders. In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials.

Treatment 52

Treatment Clinical Trials Research and Development Data 52

Cannabis Law Report

OCTOBER 13, 2021

Filed in support of the Company’s CYB004 pre-clinical development program, the PCT filing serves to increase the Company’s library of drug delivery modalities directed to optimal delivery of psychedelics and further strengthens Cybin’s growing IP portfolio. Vigorous scientific research and clinical trials are needed.

Clinical Trials 52

Clinical Trials Research and Development Treatment Conditions 52

Cannabis Law Report

JUNE 4, 2021

– Phase 2 Trial Underway. NEW YORK , June 4, 2021 /PRNewswire/ — AIkido Pharma Inc. Nasdaq: AIKI ) (“AIkido” or the “Company”) today announced that positive Phase 1 testing data was presented at the 2021 ASCO Annual Meeting June 4 , 2021. Scott Tagawa MD, MS, FACP.

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

DECEMBER 21, 2021

Numinus also made important alliances in 2021, particularly with the Multidisciplinary Association for Psychedelic Studies (MAPS) on its compassionate access trial for MDMA-assisted therapy. While its psilocybin and MDMA trials progress, the company is expanding its psychedelics research laboratory.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Cannabis Law Report

JULY 9, 2021

In June 2021, similar measures were passed in Connecticut and Texas, where medical research on psilocybin is now also legal on a statewide level. Joyce Cutler, Texas the Latest State to Legalize Psychedelic Medical Research, BLOOMBERG LAW (June 23, 2021), available at [link]. March 8, 2021). Id ; 21 CFR 312.1-10;

Law 105

Law Therapy Clinical Trials Research and Development 105

Cannabis Law Report

FEBRUARY 9, 2022

We have invested significant effort investigating and advancing Reset’s psychedelics operations throughout 2021 and believe it is now at a point where it is best placed to grow as a standalone business,” LGP CEO Fleta Solomon said. “We Post-demerger, LGP will continue to provide Reset with operational support and product supply. “The

Clinical Trials 52

Clinical Trials Research and Development Medicine Business 52

Cannabis Law Report

AUGUST 3, 2021

– Full Service, Turnkey Solution Anchored by Applied DNA Clinical Labs’ safeCircle™ Pooled COVID-19 Testing to Be Deployed Across All 25 CUNY Campuses to Facilitate Fall Re-Opening –. Fiscal 2021 Third Quarter Financial Results and Investor Conference Call. million, and contains no minimum weekly testing commitment.

Clinical Trials 105

Clinical Trials Therapy Collective Research and Development 105

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

JULY 26, 2021

SAN DIEGO, CA, July 26, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. We believe his broad leadership experience will prove invaluable as we advance our lead clinical program and execute strategies to expand our development portfolio,” said Punit Dhillon, Chief Executive Officer and Chair of Skye Bioscience.

Research and Development 105

Research and Development Clinical Trials Pharmaceutical Cannabinoids 105

Cannabis Law Report

MAY 29, 2022

In May 2021, a Nature Medicine study showed the benefits of MDMA in relieving post-traumatic stress disorder. [4] 4] In April 2021, a separate study from the New England Journal of Medicine demonstrated the efficacy of psilocybin in reducing symptoms of depression. [5] Clinical Trials and Human Subject Protections.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Puff Puff Post

OCTOBER 3, 2019

Leading the pilot research project is Dr. Eric Hollander, director of the Autism and Spectrum Program and Anxiety and Depression Program at Montefiore Hospital. Alexander Kolevzon, clinical director of the Seaver Autism Center at Mount Sinai, is skeptical due to the wide range of symptoms that are present on the autism spectrum.

Research and Development 94

Research and Development Epilepsy Clinical Trials Treatment 94

Cannabis Law Report

JULY 24, 2021

At Mydecine, we are excited to expand our drug development program to include the improvement of entactogenic compounds,” said Rob Roscow, Chief Scientific Officer. Mydecine has also successfully completed multiple acquisitions since its inception. For more information, please contact: Media Contacts.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

OCTOBER 5, 2021

30 September 2021. On 5 August 2021, the TGA announced that an Independent Expert Panel had been established to undertake the review. The Panel’s report will be considered by the Advisory Committee of Medicines Scheduling (ACMS) at the 3 November 2021 meeting. The review excludes pre-clinical trials (i.e.

Treatment 52

Treatment Conditions Medicine Clinical Trials 52

Cannabis Law Report

NOVEMBER 9, 2021

As an institution dedicated to diagnosing and treating serious blood diseases and with the ability to pursue investigational medicines from development to manufacture and clinical trial for patients who have exhausted all approved treatment options, having a cost-effective and rapid production chain is integral to ÚHKT’s mission.

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52

Cannabis Law Report

NOVEMBER 15, 2021

CRO orders typically provide a means to evaluate LinearDNA within a customer’s preclinical development program. 2021 Aug 26;23:119-127. eCollection 2021 Dec 10. Hurry, 917-733-5573, sanjay.hurry@adnas.com Program Manager: Brian Viscount, 631-240-8877, brian.viscount@adnas.com Web: www.adnas.com Twitter: @APDN.

Research and Development 52

Research and Development Therapy Clinical Trials Supply Chain 52

Cannabis Law Report

AUGUST 25, 2021

“Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies.

Clinical Trials 111

Clinical Trials Research and Development Therapy Conditions 111

Cannabis Law Report

JUNE 8, 2021

Englewood Cliffs, NJ, June 08, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain.

Patients 92

Patients Research and Development Clinical Trials Chronic Pain 92

Cannabis Law Report

JUNE 2, 2021

Aggregate testing results will be reported to the director of the summer camp via safeCircle’s integration with CLEARED4, the Company’s pooled surveillance testing program partner, through CLEARED4’s smartphone-based online health safety management and reporting solution. Testing will be conducted from mid-June through end-July.

Clinical Trials 82

Clinical Trials Therapy Research and Development Collective 82

Cannabis Law Report

FEBRUARY 10, 2022

Psilocybin’s therapeutic benefits are so promising that Denver, Colorado became the first city to decriminalize psilocybin in May 2019, and in 2020, Oregon passed Measure 109, which paved the road for a program allowing for legal manufacture, delivery, and administration of psilocybin to clients at supervised, licensed facilities in the state.

DEA 52

DEA Clinical Trials Policy Research and Development 52

TheAnswerPage

JANUARY 11, 2022

According to state laws, in order to purchase medical marijuana products, a patient must first obtain a recommendation (not a prescription) for medical marijuana from a clinician and enroll in the state medical marijuana program. Nov 24 2021. Journal of Clinical Gynecology and Obstetrics, North Amer, 0 Nov 2021.

Patients 98

Patients Education Marijuana Therapy 98